Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.

In English

Författare

  • Berit Kriström
  • A Stefan Aronson
  • Jovanna Dahlgren
  • Jan Gustafsson
  • Maria Halldin
  • Sten Ivarsson
  • Nils-Eric Nilsson
  • Johan Svensson
  • Torsten Tuvemo
  • Kerstin Albertsson-Wikland

Summary, in English

Context: Weight-based growth hormone (GH) dosing results in a wide variation in growth response in children with GH deficiency (GHD) or idiopathic short stature (ISS). Objective: The hypothesis tested was whether individualized GH doses, based on variation in GH responsiveness estimated by a prediction model, reduced variability in growth response around a set height target compared with a standardized weight-based dose. Setting: 153 short prepubertal children diagnosed with isolated GHD or ISS (n=43) and >/=1 SDS below mid-parental height standard deviation score(MPHSDS) were included in this 2-year multicenter study. Intervention: The children were randomized to either a standard (43 microg/kg/d) or an individualized GH dose (17-100 microg/kg/d). Main outcome measure: Deviation of HeightSDS from individual MPHSDS (diffMPHSDS). The primary endpoint was difference in the range of 'diffMPHSDS' between the two groups. Results: diffMPHSDS range was reduced by 32% in the individualized-dose group relative to the standard-dose group (p<0.003), whereas the mean 'diffMPHSDS' was equal: -0.42+/-0.46 and -0.48+/-0.67, respectively. Gain in HeightSDS 0-2 yrs was equal for the GH-deficient and the ISS groups; 1.31+/-0.47 and 1.36+/-0.47, respectively, when ISS was classified on the basis of maximum GH peak on the arginine-insulin tolerance test or 24h profile. Conclusion: Individualized GH doses during catch-up growth significantly reduces the proportion of unexpectedly good and poor responders around a predefined individual growth target and results in equal growth responses in children with GHD and ISS.

Publiceringsår

2009

Språk

Engelska

Sidor

483-490

Publikation/Tidskrift/Serie

Journal of Clinical Endocrinology and Metabolism

Volym

Nov 11

Dokumenttyp

Artikel i tidskrift

Förlag

Oxford University Press

Ämne

  • Endocrinology and Diabetes
  • Pediatrics

Status

Published

Forskningsgrupp

  • Paediatric Endocrinology

ISBN/ISSN/Övrigt

  • ISSN: 1945-7197